RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Ascendis Pharma A/S Equity 2024

Ascendis Pharma A/S Equity

-145.7 M EUR

Ascendis Pharma A/S Dividend yield

Ticker

ASND

ISIN

US04351P1012

WKN

A14M6X

In 2024, Ascendis Pharma A/S's equity was -145.7 M EUR, a -155.33% increase from the 263.3 M EUR equity in the previous year.

Ascendis Pharma A/S Aktienanalyse

What does Ascendis Pharma A/S do?

Ascendis Pharma A/S is a biopharmaceutical company based in Denmark that focuses on developing innovative therapies for diseases that currently have no suitable treatment options. The company was founded in 2007 and is headquartered in Hellerup, Denmark. History The company was founded by an experienced team of researchers and professionals from the pharmaceutical and biotech industry who recognized the need for new therapies for chronic diseases. They used innovative technologies to develop drugs that would have longer-lasting effects, thus reducing the need for frequent doses. In 2015, the company went public to raise additional capital for the further development of their technologies and products. Business model Ascendis Pharma A/S is working on the development of drugs using a proprietary technology platform called TransCon technology. TransCon technology is a novel delivery system that allows drugs to remain in the body for longer periods of time, thus achieving a continuous effect. This leads to a reduced need for frequent doses, improving patient care and adherence to therapy. The company follows an asset-based business model strategy. It aims to market its products globally through a licensing and partnering approach. By partnering with established pharmaceutical companies, Ascendis Pharma A/S can introduce their drugs into broader markets while ensuring resources for further research and development. Divisions Ascendis Pharma A/S has two main business divisions: 1. Endocrinology: Ascendis Pharma A/S is a leader in the development of therapies for diseases caused by hormonal disorders. The TransCon technology is used for the delivery of hormones such as growth hormone, parathyroid hormone, follicle-stimulating hormone, and luteinizing hormone to achieve continuous release in the body. 2. Oncology: The company also utilizes the TransCon technology for the delivery of cytokines for cancer immunotherapy. Products The most well-known product of Ascendis Pharma A/S is TransCon Growth Hormone, a growth hormone therapy that has longer-lasting effects and only needs to be administered once a week for children with growth hormone deficiency. The company also has TransCon PTH and TransCon CNP in the endocrinology pipeline. In oncology, the company has developed TransCon IL-2, an interleukin-2 immunotherapy for cancer. Summary Ascendis Pharma A/S is an innovative biopharmaceutical company specializing in the development of therapies for chronic diseases. The company utilizes its proprietary technology platform, TransCon technology, to develop drugs that have longer-lasting effects and reduce the need for frequent doses. It focuses on endocrinology and oncology and follows an asset-based business model strategy by entering partnerships with established pharmaceutical companies. The most well-known product of Ascendis Pharma A/S is TransCon Growth Hormone. Ascendis Pharma A/S ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Ascendis Pharma A/S's Equity

Ascendis Pharma A/S's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Ascendis Pharma A/S's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Ascendis Pharma A/S's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Ascendis Pharma A/S's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Ascendis Pharma A/S’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Ascendis Pharma A/S Stock

What is the equity of Ascendis Pharma A/S this year?

Ascendis Pharma A/S has equity of -145.7 M EUR this year.

What was the equity of Ascendis Pharma A/S compared to the previous year?

The equity of Ascendis Pharma A/S has increased/decreased by -155.33% decreased compared to the previous year.

What impact does a high equity have on investors of Ascendis Pharma A/S?

A high equity is advantageous for investors of Ascendis Pharma A/S as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Ascendis Pharma A/S?

A low equity can be a risk for investors of Ascendis Pharma A/S, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Ascendis Pharma A/S affect the company?

An increase in equity of Ascendis Pharma A/S can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Ascendis Pharma A/S affect the company?

A reduction in equity of Ascendis Pharma A/S can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Ascendis Pharma A/S?

Some factors that can affect the equity of Ascendis Pharma A/S include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Ascendis Pharma A/S so important for investors?

The equity of Ascendis Pharma A/S is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Ascendis Pharma A/S take to change the equity?

To change equity, Ascendis Pharma A/S can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Ascendis Pharma A/S pay?

Over the past 12 months, Ascendis Pharma A/S paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Ascendis Pharma A/S is expected to pay a dividend of 0 EUR.

What is the dividend yield of Ascendis Pharma A/S?

The current dividend yield of Ascendis Pharma A/S is .

When does Ascendis Pharma A/S pay dividends?

Ascendis Pharma A/S pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Ascendis Pharma A/S?

Ascendis Pharma A/S paid dividends every year for the past 0 years.

What is the dividend of Ascendis Pharma A/S?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Ascendis Pharma A/S located?

Ascendis Pharma A/S is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ascendis Pharma A/S kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ascendis Pharma A/S from 5/15/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 5/15/2024.

When did Ascendis Pharma A/S pay the last dividend?

The last dividend was paid out on 5/15/2024.

What was the dividend of Ascendis Pharma A/S in the year 2023?

In the year 2023, Ascendis Pharma A/S distributed 0 EUR as dividends.

In which currency does Ascendis Pharma A/S pay out the dividend?

The dividends of Ascendis Pharma A/S are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Ascendis Pharma A/S stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Ascendis Pharma A/S

Our stock analysis for Ascendis Pharma A/S Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ascendis Pharma A/S Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.